OncoBay Clinical, one of Moffitt Cancer Center’s for-profit subsidiaries, has partnered with Clinscience, a global clinical research organization based in Warsaw, Poland. The investment gives NEUCA Group, Clinscience’s parent company, a majority equity stake in OncoBay. Both companies will work together to advance immuno-oncology research for a global portfolio of clients.
Moffitt created OncoBay Clinical in 2019 as a boutique clinical research organization that offers streamlined, custom-curated services for biopharma and biotech companies conducting research in the immuno-oncology space. During this time, OncoBay has grown to providing services to more than 60 customers, with many trials conducted in tandem with Clinscience. This new partnership builds upon a two-year relationship with Clinscience.
“Moffitt made an investment three years ago when it launched OncoBay, and in that short period of time we have taken this concept to a global entity with an international research footprint,” said James Mulé, IPhD, associate center director of Translational Science at Moffitt and OncoBay advisor. “This new partnership with Clinscience will allow us to continue to provide tailored immuno-oncology on a much larger scale.”
“This innovation collaboration gives us an exciting opportunity to build upon our clinical expertise, innovative analytics and data assessment tools to impact immuno-oncology research globally. The goal is to transform and accelerate discoveries to reach patients more quickly,” said Krystyna Kowalczyk, OncoBay CEO and co-founder.
Kowalczyk will remain CEO of the combined OncoBay and Clinscience operation. She and
Dannelle Palmer, OncoBay’s chief operating officer, will also join NEUCA Group’s leadership team.
Pillsbury Winthrop Shaw Pittman LLP served as legal adviser to NEUCA Group and Clinscience in the transaction. Ropes & Gray LLP served as legal adviser to OncoBay and Moffitt.